Patents by Inventor Roland Jakob
Roland Jakob has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160137643Abstract: The present invention relates to compounds of general formula I wherein R1, R2, R3 and R4 are as defined herein which maybe used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.Type: ApplicationFiled: January 27, 2016Publication date: May 19, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Jens-Uwe Peters, Juergen Wichmann
-
Patent number: 9315502Abstract: The present invention relates to compounds of general formula wherein Ar is phenyl or pyridinyl; X1 is N or CH, X2 is N or CH, with the proviso that only one of X1 or X2 is N and the other is CH; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, cyano or S(O)2-lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof.Type: GrantFiled: May 27, 2015Date of Patent: April 19, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Patent number: 9284321Abstract: The present invention relates to compounds of general formula I or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, R and n are as defined herein. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.Type: GrantFiled: February 4, 2015Date of Patent: March 15, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Patent number: 9276499Abstract: A method for operating an electrical circuit is described. The electrical circuit is equipped with a power converter (10) that has at least one series connection (11, 12, 13) consisting of at least four power semiconductor elements. The electrical circuit is equipped with at least one capacitor (Cd1, Cd2) connected in parallel to the series connection (11, 12, 13). In the power converter (10), at least one resistor has been connected in parallel to the middle two power semiconductor elements. In the method, at least one of the power semiconductor elements is conductively connected and in this way a discharging current is generated from the capacitor (Cd1, Cd2) through the conductively connected power semiconductor element and the resistor.Type: GrantFiled: April 18, 2013Date of Patent: March 1, 2016Assignee: GE Energy Power Conversion GMBHInventors: Roland Jakob, Piotr Sadowski
-
Publication number: 20160046583Abstract: The present invention relates to the use of compounds of general formula wherein R1 is phenyl or pyridinyl, which are optionally substituted by halogen, cyano or lower alkyl substituted by halogen, or is dihydro-pyran-4-yl; R2 is hydrogen or lower alkyl; R3 is —(CHR)n-phenyl, optionally substituted by lower alkoxy or S(O)2-lower alkyl, or is heterocycloalkyl, optionally substituted by ?O and lower alkyl, or is —(CH2)n-five or six membered heteroaryl, optionally substituted by lower alkyl, or is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, —NR—S(O)2-lower alkyl, —(CH2)n-cycloalkyl or —(CH2)n—S(O)2-lower alkyl; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl ring, selected from the group consisting of 1,1-dioxo-thiomorpholinyl, morpholinyl, or pyrrolidinyl, optionally substituted by hydroxyl; R is hydrogen or lower alkyl; n is 0, 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixtureType: ApplicationFiled: October 29, 2015Publication date: February 18, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Rainer E. Martin, Juergen Wichmann
-
Publication number: 20160016963Abstract: The present invention relates to compounds of general formula I wherein R1 is halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or cyano; R2 is hydrogen, CF3 or lower alkyl; R3 is hydrogen, lower alkyl, lower alkenyl, lower alkinyl, heterocycloalkyl, lower alkyl substituted by cyano, cyano, benzyl substituted by halogen, 2-oxa-6-aza-spiro[3.3]hept-6-yl or is lower alkoxy substituted by halogen; X is —CH2— or —CH2—CH2—; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof.Type: ApplicationFiled: September 28, 2015Publication date: January 21, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Publication number: 20160002177Abstract: The present invention relates to compounds of formula wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.Type: ApplicationFiled: June 26, 2015Publication date: January 7, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Caterina BISSANTZ, René Bonnafous, Bernd Buettelmann, Roland Jakob-Roetne, Christian Lerner, Markus Rudolph
-
Patent number: 9214873Abstract: A method for operating an electrical power rectifier. The power rectifier comprises at least two branches that are connected in parallel to each other, each of the branches comprising at least two power semiconductor elements that are connected in series. The collector-emitter voltage Vce(t) and/or the collector current Ic(t) of one of the power semiconductor elements is detected by means of the method. Furthermore, it is determined whether at least one of the following conditions is met: dVce(t)/dt<(dVce/dt)crit, and/or dIc(t)/dt<(dIc/dt)crit, and or Ic(t_ent)<Iccrit. If at least one of the aforementioned conditions has been met, the gate-emitter voltage of at least one of the power semiconductor elements is increased.Type: GrantFiled: December 18, 2013Date of Patent: December 15, 2015Assignee: GE Energy Power Conversion GmbHInventors: Roland Jakob, Piotr Sadowski, Thomas Bruckner, Thomas Basler
-
Publication number: 20150259334Abstract: The present invention relates to compounds of general formula wherein Ar1/Ar2 are phenyl or a 5 or 6-membered heteroaryl; R1/R2 is hydrogen, halogen, lower alkyl, CF3 or lower alkoxy; n,m are 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, with the exception of the compound 2,1-benzisoxazole, 3-(4-chlorophenyl)-5-(1-phenyl-1H-pyrazol-5 -yl)-.Type: ApplicationFiled: January 22, 2015Publication date: September 17, 2015Applicant: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Publication number: 20150259341Abstract: The present invention relates to compounds of general formula wherein Ar is phenyl or pyridinyl; X1 is N or CH, X2 is N or CH, with the proviso that only one of X1 or X2 is N and the other is CH; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, cyano or S(0)2-lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof.Type: ApplicationFiled: May 27, 2015Publication date: September 17, 2015Applicant: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Publication number: 20150252044Abstract: The present invention relates to the use of compounds of general formula wherein R? is hydrogen or lower alkyl; R1 is halogen, lower alkyl, cycloalkyl or cyano; or is phenyl, optionally substituted by one to three substituents, selected from lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, halogen, cyano, hydroxy, C(O)—NH-lower alkyl, CH2—C(O)—NH-lower alkyl, CH2—NH—C(O)-lower alkyl, CH2NH2, S(O)2CH3, S(O)2N(CH3)2, or by heterocycloalkyl groups; or is pyrazol-1, 4 or 5-yl, optionally substituted by lower alkyl; or is thiazol-5-yl, optionally substituted by one or two lower alkyl groups; or is pyridine 2, 3 or 4-yl, optionally substituted by lower alkyl, lower alkoxy, halogen or N(CH3)2; or is 3,6-dihydro-2H-pyran; or is benzo[d][1,3]dioxol-5-yl; or is 2,3-dihydrobenzo[b][1,4]dioxin-6-yl; R2 is hydrogen, lower alkyl or lower alkyl substituted by alkoxy; R3 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy,Type: ApplicationFiled: May 20, 2015Publication date: September 10, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Rainer E. Martin, Jens-Uwe Peters, Juergen Wichmann
-
Publication number: 20150246922Abstract: The present invention relates to compounds of general formula I or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, R and n are as defined herein. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.Type: ApplicationFiled: February 4, 2015Publication date: September 3, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Publication number: 20150203472Abstract: The present invention relates to compounds of general formula wherein R1 hydrogen, lower alkyl, halogen or lower alkyl substituted by halogen; R2 is hydrogen or halogen; X1 is N or CH; X2 is N or CH; with the proviso that only one of X1 or X2 is N; X3 is C(R) or N; and R is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy or SO2-lower alkyl; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof.Type: ApplicationFiled: March 31, 2015Publication date: July 23, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Patent number: 9073908Abstract: The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A ?5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.Type: GrantFiled: June 12, 2013Date of Patent: July 7, 2015Assignee: ROCHE PALO ALTO LLCInventors: Bernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Matthew C. Lucas, Andrew Thomas
-
Patent number: 8879292Abstract: An electrical circuit for a power converter is described. The circuit has been provided with several semiconductor switches and capacitors used for operating the power converter. A brake resistance for lowering energy is provided and is connected to the semiconductor switches provided without the need for an additional switch. The operation of the power converter and the current flowing through the brake resistance can be controlled by means of the existing semiconductor switches.Type: GrantFiled: November 20, 2012Date of Patent: November 4, 2014Assignee: GE Energy Power Conversion GmbHInventors: Roland Jakob, Thomas Brückner
-
Patent number: 8877782Abstract: The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A ?5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.Type: GrantFiled: June 12, 2013Date of Patent: November 4, 2014Assignee: Roche Palo Alto LLCInventors: Bernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Matthew C. Lucas, Andrew Thomas
-
Patent number: 8877783Abstract: The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A ?5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.Type: GrantFiled: June 12, 2013Date of Patent: November 4, 2014Assignee: Roche Palo Alto LLCInventors: Bernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Matthew C. Lucas, Andrew Thomas
-
Patent number: 8846719Abstract: The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A ?5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.Type: GrantFiled: June 12, 2013Date of Patent: September 30, 2014Assignee: Roche Palo Alto LLCInventors: Bernd Buettelmann, Roland Jakob-Roetne, Henner Knust, Matthew C. Lucas, Andrew Thomas
-
Publication number: 20140177306Abstract: A method for operating an electrical power rectifier. The power rectifier comprises at least two branches that are connected in parallel to each other, each of the branches comprising at least two power semiconductor elements that are connected in series. The collector-emitter voltage Vce(t) and/or the collector current Ic(t) of one of the power semiconductor elements is detected by means of the method. Furthermore, it is determined whether at least one of the following conditions is met: dVce(t)/dt<(dVce/dt)crit, and/or dIc(t)/dt<(dIc/dt)crit, and or Ic(t13 ent)<Iccrit. If at least one of the aforementioned conditions has been met, the gate-emitter voltage of at least one of the power semiconductor elements is increased.Type: ApplicationFiled: December 18, 2013Publication date: June 26, 2014Inventors: Roland Jakob, Piotr Sadowski, Thomas Bruckner, Thomas Basler
-
Publication number: 20140077622Abstract: A circuit arrangement connected to an electrical circuit including a transformer with primary winding connected to the electric power grid and secondary winding connected to a power converter with a capacitor, the circuit arrangement has a primary winding coupled to the auxiliary winding, which is connected to a switching device.Type: ApplicationFiled: September 13, 2013Publication date: March 20, 2014Applicant: GE Energy Power Conversion GmbHInventors: Martin Geske, Roland Jakob